Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD

W. Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham and the principal investigator of SURMOUNT-2, joins our hosts to provide perspective on several topics, including the FDA’s approval of tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and more.

Key Timestamps

01:04 - Guest Introduction

03:45 - FDA Indication for Obesity

08:45 - SURMOUNT-2

17:40 - SURMOUNT-3 and -4

22:00 - Future of Incretin Therapies